Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273480 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01273480 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 12 participants.
The verdict
NCT01273480, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential effects of rifampin on blood levels of trabectedin after administration to patients with advanced malignancies.
Interventions
- DRUG Sequence 1
- DRUG Sequence 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01273480
The ClinicalTrials.gov registry entry for NCT01273480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sequence 1 is the first listed.
NCT01273480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01273480 about?
NCT01273480 is a clinical study titled "A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies". The purpose of this study is to evaluate the potential effects of rifampin on blood levels of trabectedin after administration to patients with advanced malignancies.
What is the current status of trial NCT01273480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01273480?
The interventions under investigation include: Sequence 1 (DRUG), Sequence 2 (DRUG).
Who is sponsoring clinical trial NCT01273480?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.